Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | President, Global Head of R&D | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-23 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-06-23 · Sale · Disposed 1,068 · Balance 0 F5: Each American Depositary Share represents 13 Ordinary Shares. F6: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,681,004 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,681,004 |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 601,965 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 601,965 F1: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. |
| RMB SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
Holding disclosure · report date 2026-06-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 0 F2: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market. F3: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F4: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership.
F2: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market.
F3: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924).
F4: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, has contributed RMB10 million to the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose.
F5: Each American Depositary Share represents 13 Ordinary Shares.
F6: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 21:14 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,068 | $276.74 | $295,552.98 |
DisclosureSEC source: 0001852291-26-000007 · wk-form4_1782422092.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 21:19 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,169 | $265.39 | $310,235.88 |
DisclosureSEC source: 0001852291-26-000006 · wk-form4_1781817568.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.385 to $265.775, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:55 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 229,775 | $0.00 Strike: $20.81 | $0.00 |
DisclosureSEC source: 0001852291-26-000005 · wk-form4_1781560527.xml · derivative · entry 5 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,775 Underlying: Ordinary Shares · 229,775 shares Expires 2036-06-10 F9 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F9 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 11, 2026 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:55 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 756 | $261.00 | $197,317.59 |
DisclosureSEC source: 0001852291-26-000005 · wk-form4_1781560527.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.87 to $261.16, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:55 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 118,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001852291-26-000005 · wk-form4_1781560527.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,710,085 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 11, 2026, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 21:25 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 40 | $270.73 | $10,829.20 |
DisclosureSEC source: 0001852291-26-000004 · wk-form4_1781126723.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 21:25 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,327 | $269.34 | $357,417.63 |
DisclosureSEC source: 0001852291-26-000004 · wk-form4_1781126723.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.88 to $269.80, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 00:13 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 55,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001852291-26-000003 · wk-form4_1773187992.xml · nonDerivative · entry 2 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,619,059 F2 · shares: Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 00:13 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 112,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001852291-26-000003 · wk-form4_1773187992.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,564,030 F1 · shares: Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:12 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 427,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001852291-26-000002 · wk-form4_1767651119.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,451,424 F1 · security: Represents securities underlying restricted share units. 1/4 of the securities will vest on each anniversary of December 31, 2025, subject to continued service through each such date. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:10 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 5,000 | $350.06 | $1,750,311.50 |
DisclosureSEC source: 0001651308-25-000142 · wk-form4_1757625045.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| July 30, 2025 Filed Jul 31, 2025 21:05 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 259 | $305.00 | $78,995.00 |
DisclosureSEC source: 0001651308-25-000122 · wk-form4_1753995922.xml · nonDerivative · entry 7 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 21:05 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 800 | $304.16 | $243,330.40 |
DisclosureSEC source: 0001651308-25-000122 · wk-form4_1753995922.xml · nonDerivative · entry 6 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 259 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.94 to $304.50, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 21:05 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 292 | $302.92 | $88,454.07 |
DisclosureSEC source: 0001651308-25-000122 · wk-form4_1753995922.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 1,059 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.76 to $303.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 21:05 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 2,949 | $302.00 | $890,595.94 |
DisclosureSEC source: 0001651308-25-000122 · wk-form4_1753995922.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 1,351 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.74 to $302.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 20:54 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 700 | $300.00 | $210,000.00 |
DisclosureSEC source: 0001651308-25-000120 · wk-form4_1753217651.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:09 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,028 | $260.00 | $267,280.00 |
DisclosureSEC source: 0001651308-25-000118 · wk-form4_1750885786.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 21:10 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 470 | $251.37 | $118,141.55 |
DisclosureSEC source: 0001651308-25-000113 · wk-form4_1750281039.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F8 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 21:10 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,177 | $266.40 | $313,557.51 |
DisclosureSEC source: 0001651308-25-000113 · wk-form4_1750281039.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.28 to $266.53, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:44 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 162,565 | $0.00 Strike: $20.26 | $0.00 |
DisclosureSEC source: 0001651308-25-000107 · wk-form4_1749764650.xml · derivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,565 Underlying: Ordinary Shares · 162,565 shares Expires 2035-06-09 F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F6 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:44 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 86,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000107 · wk-form4_1749764650.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,058,304 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:56 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 300 | $255.30 | $76,590.00 |
DisclosureSEC source: 0001651308-25-000102 · wk-form4_1749588973.xml · nonDerivative · entry 7 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.99 to $255.51, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:56 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 300 | $253.19 | $75,956.01 |
DisclosureSEC source: 0001651308-25-000102 · wk-form4_1749588973.xml · nonDerivative · entry 6 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.05 to $253.34, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:56 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 202 | $251.89 | $50,882.31 |
DisclosureSEC source: 0001651308-25-000102 · wk-form4_1749588973.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.64 to $252.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:56 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 600 | $250.71 | $150,424.98 |
DisclosureSEC source: 0001651308-25-000102 · wk-form4_1749588973.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 802 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.33 to $251.27, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:22 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 69,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000045 · wk-form4_1741393346.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990,171 F1 · shares: Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 400 | $260.17 | $104,067.48 |
DisclosureSEC source: 0001651308-25-000021 · wk-form4_1740521163.xml · nonDerivative · entry 9 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.81 to $260.25, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,782 | $258.73 | $461,057.75 |
DisclosureSEC source: 0001651308-25-000021 · wk-form4_1740521163.xml · nonDerivative · entry 8 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 400 F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.64 to $259.155, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 437 | $258.18 | $112,825.53 |
DisclosureSEC source: 0001651308-25-000021 · wk-form4_1740521163.xml · nonDerivative · entry 7 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 2,182 F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.60 to $258.59, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 479 | $256.70 | $122,957.24 |
DisclosureSEC source: 0001651308-25-000021 · wk-form4_1740521163.xml · nonDerivative · entry 6 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 2,619 F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.34 to $257.30, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 575 | $255.86 | $147,116.97 |
DisclosureSEC source: 0001651308-25-000021 · wk-form4_1740521163.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 3,098 F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.33 to $256.21, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 22:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,327 | $254.82 | $338,149.06 |
DisclosureSEC source: 0001651308-25-000021 · wk-form4_1740521163.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 3,673 F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.02 to $254.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 22:29 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 5,000 | $220.35 | $1,101,774.00 |
DisclosureSEC source: 0001651308-24-000126 · wk-form4_1727821791.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2024. F1 · ownership.nature: These securities are held by Wang Holdings LLC, the limited liability company interests of which are owned by the Reporting Person, his spouse and a trust created by the Reporting Person for the benefit of his spouse and children, for which the Reporting Person disclaims beneficial ownership. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2 | $161.10 | $322.20 |
DisclosureSEC source: 0001651308-24-000078 · wk-form4_1719437109.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,062 | $159.80 | $169,707.60 |
DisclosureSEC source: 0001651308-24-000078 · wk-form4_1719437109.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.26 to $160.16, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 841 | $153.75 | $129,304.76 |
DisclosureSEC source: 0001651308-24-000073 · wk-form4_1718918744.xml · nonDerivative · entry 8 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F11 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.54 to $154.29, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $159.90 | $47,970.57 |
DisclosureSEC source: 0001651308-24-000073 · wk-form4_1718918744.xml · nonDerivative · entry 7 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 841 F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.40 to $160.33, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 485 | $159.42 | $77,320.69 |
DisclosureSEC source: 0001651308-24-000073 · wk-form4_1718918744.xml · nonDerivative · entry 6 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,141 F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.12 to $159.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 478 | $159.00 | $76,001.09 |
DisclosureSEC source: 0001651308-24-000073 · wk-form4_1718918744.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,626 F7 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.885 to $159.2191, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 237 | $158.50 | $37,564.55 |
DisclosureSEC source: 0001651308-24-000073 · wk-form4_1718918744.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,104 F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.10 to $159.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:03 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 318,253 | $0.00 Strike: $12.23 | $0.00 |
DisclosureSEC source: 0001651308-24-000067 · wk-form4_1717794229.xml · derivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,253 Underlying: Ordinary Shares · 318,253 shares Expires 2034-06-04 F6 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F6 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F7 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:03 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 168,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000067 · wk-form4_1717794229.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,768,962 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 21:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 5 | $183.15 | $915.75 |
DisclosureSEC source: 0001651308-23-000103 · wf-form4_168790103763021.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 21:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,103 | $181.91 | $200,651.58 |
DisclosureSEC source: 0001651308-23-000103 · wf-form4_168790103763021.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:53 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,325 | $192.42 | $254,955.44 |
DisclosureSEC source: 0001651308-23-000092 · wf-form4_168730157221116.xml · nonDerivative · entry 4 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F6 · security: Each American Depositary Share represents 13 Ordinary Shares. F7 · kind: The sale was effected pursuant to mandatory tax withholding provisions in the Reporting Person's restricted share unit award agreements in connection with the vesting of two restricted share unit awards previously granted to the Reporting Person. 1/4th of the securities under one award will vest on each anniversary of June 17, 2020 and under the other award on each anniversary June 16, 2021, subject to continued service. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.4118 to $192.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:53 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 507,234 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001651308-23-000092 · wf-form4_168730157221116.xml · derivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,234 Underlying: Ordinary Shares · 507,234 shares Expires 2033-06-14 F9 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F9 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:53 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 133,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-23-000092 · wf-form4_168730157221116.xml · nonDerivative · entry 1 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,614,431 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 21:46 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 116 | $226.15 | $26,233.53 |
DisclosureSEC source: 0001651308-23-000079 · wf-form4_168634717636068.xml · nonDerivative · entry 7 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.835 to $226.62, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 21:46 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 111 | $225.27 | $25,005.20 |
DisclosureSEC source: 0001651308-23-000079 · wf-form4_168634717636068.xml · nonDerivative · entry 6 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.81 to $225.80, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 21:46 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 161 | $224.04 | $36,070.49 |
DisclosureSEC source: 0001651308-23-000079 · wf-form4_168634717636068.xml · nonDerivative · entry 5 Wang Lai · CIK 0001852291 · Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.71 to $224.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.